Shatavari (Asparagus racemosus): Complete Research Profile for Women’s Health

Shatavari is the Ayurvedic drug prepared from the tuberous roots of Asparagus racemosus Willd. Its reputation is especially associated with nourishment, convalescence, reproductive health and lactation. The Ayurvedic Pharmacopoeia of India (API) identifies the root as the official drug and records actions including balya, medhya, rasayana, vrishya and stanyakara.

Modern investigation has focused on steroidal saponins, lactation, menopausal symptoms, stress-related outcomes, antioxidant activity and gastric protection. Human evidence is most developed for lactation and short-term menopausal or perimenopausal symptoms, while many other applications remain supported principally by laboratory or animal experiments. Results obtained with a particular root powder or standardized extract do not automatically apply to every Shatavari product.

Ayurvedic Identity, Properties and Uses

The API monograph describes Shatavari as predominantly sweet and bitter in taste, heavy and unctuous in quality, cooling in potency and sweet after digestion. Its listed therapeutic uses include amlapitta, parinama shula, puerperal disorders, disorders of breast milk and diminished lactation. These indications describe the Ayurvedic application of the drug and are not equivalent to modern disease-treatment claims.

The API dose refers to the pharmacopoeial root drug; concentrated extracts require product-specific dosing. Shatavari should also not be placed in Charaka’s formal Stanyajanana Mahakashaya, which contains a different ten-drug group. Its lactation use is nevertheless supported by the API descriptions stanyakara and use in stanya kshaya.

Phytochemistry: What Has Actually Been Identified

Shatavari root contains several classes of constituents, but no single isolated molecule has been established as its sole clinical active ingredient. Root-isolation studies have characterized numerous steroidal saponins, including shatavarin I, IV, V and VI–X, immunoside and asparanin A, together with sterols, triterpenes and phenolic constituents.

Asparagamine A was historically reported as an alkaloid from Shatavari, but later chemical and botanical analysis did not detect it in authentic Asparagus racemosus and attributed the earlier finding to likely misidentification involving Stemona material. The presence of steroidal saponins also does not by itself establish that the herb acts like a human steroid hormone.

Galactagogue Activity: Promising but Product-Specific

Lactation is the best-documented traditional and clinical domain for Shatavari. The API lists it as stanyakara and for stanya kshaya. Controlled trials have not all produced the same result, however, and several investigated multi-ingredient preparations rather than Shatavari alone.

• A 1996 randomized trial enrolled 64 women with lactational inadequacy. The tested mixture contained Shatavari with several other ingredients, and the completed cases showed no advantage over placebo in prolactin change, infant weight gain or supplemental feeding.
• A 2011 double-blind trial randomized 60 nursing mothers to fresh Shatavari root at 20 mg/kg three times daily or rice-powder placebo for 30 days. Prolactin increased by 33% from baseline in the Shatavari group and by 10% in the placebo group; infant weight increased by 16% and 6%, respectively. The varied entry complaints and absence of optimized breastfeeding technique before treatment limit interpretation.
• A 2022 double-blind trial of a food bar containing Shatavari reported greater milk volume and a shorter time to breast fullness than a matched bar without Shatavari, with 39 participants in each group.
• A 2025 randomized, double-blind trial enrolled 120 postpartum women and analyzed 113 completers. A standardized root extract used for 72 hours shortened the time to breast fullness and increased expressed milk volume at 72 hours compared with placebo; no significant adverse events were reported.

Taken together, these findings support a plausible lactation benefit, particularly during early postpartum use, but they do not establish a universal dose or guarantee a meaningful long-term breastfeeding outcome. A galactagogue should not replace assessment of latch, feeding frequency, maternal illness, infant weight, hydration or other correctable causes of low milk supply. Breastfeeding use should be coordinated with a qualified clinician or lactation professional.

Menopause, Perimenopause and Menstrual Health

The commercial phrase “balances female hormones” is too broad. Recent trials have evaluated defined symptom scales and selected laboratory outcomes, but they do not establish that Shatavari normalizes every reproductive hormone or treats every cause of irregular menstruation.

A 2024 double-blind multicenter trial administered a standardized root extract at 250 mg twice daily for 60 days and reported improvement in several menopausal symptom and quality-of-life measures compared with placebo. An eight-week 2025 perimenopause trial randomized 80 women to 300 mg once daily or placebo; 73 completed the per-protocol analysis, with greater improvement in Menopause Rating Scale and perceived-stress scores in the extract group. Another 2025 multicenter trial enrolled 135 women for eight weeks and found larger Menopause Rating Scale reductions with Shatavari than placebo, while changes in measured hormones and individual vasomotor outcomes were less consistent.

A 2026 pilot trial in 70 women with polycystic ovary syndrome tested 300 mg of a standardized extract daily for 12 weeks. Ovarian volume, the primary outcome, did not differ significantly from placebo, and serum reproductive hormones were not significantly changed. Follicle count, endometrial thickness and perceived-stress scores improved, but ovulation, menstrual-cycle normalization and fertility were not directly established. Shatavari therefore should not replace diagnosis and established management of abnormal bleeding, infertility, PCOS, fibroids, endometriosis or severe menopausal symptoms.

Rasayana, Medhya and Stress-Related Effects

The API lists Shatavari as both rasayana and medhya. This supports an Ayurvedic description of restorative and intellect-supporting action, but it should not be confused with Charaka’s specifically described Medhya Rasayana preparations of Mandukaparni, Yashtimadhu, Guduchi and Shankhapushpi.

Rodent experiments have reported effects on anxiety-like behaviour, the hypothalamic-pituitary-adrenal axis and brain monoamines after administration of Shatavari extracts. These models provide a basis for further stress-related investigation but do not establish equivalence to diazepam, antidepressants or validated human therapy. Human trials have recorded improvements in perceived-stress scores in selected perimenopause and PCOS populations, yet Shatavari has not been established as a stand-alone treatment for anxiety, depression or chronic stress disorders.

Antioxidant and Gastroprotective Findings

Antioxidant activity is demonstrated mainly in chemical assays and experimental models. A 2004 isolation study identified racemofuran from the root and reported DPPH radical-scavenging activity with an IC50 of 130 micromolar. Such an assay identifies chemical activity under laboratory conditions; it does not define an effective human dose or establish prevention of oxidative-stress-related disease.

Gastric protection also has a traditional and preclinical basis. The API lists amlapitta and parinama shula among Shatavari’s uses. In a 2005 rat study, methanolic root extract at 100 mg/kg daily for 15 days reduced ulcer index, gastric secretion and acidity in indomethacin- and stress-induced ulcer models, with effects described as comparable to ranitidine in that experiment. This finding does not make Shatavari a substitute for medical assessment of persistent reflux, ulcer symptoms, gastrointestinal bleeding or Helicobacter pylori infection.

Safety, Dose and Responsible Use

Short clinical trials have generally reported few adverse events, but long-term human safety, pregnancy safety and herb-drug interactions are not well characterized. The API’s 3–6 g dose applies to the official root drug, whereas modern trials have used standardized extracts in much smaller milligram amounts. These forms are not dose-equivalent.

Breastfeeding and Pregnancy

Small lactation trials have not identified major maternal or infant adverse effects, yet LactMed notes that safety has not been rigorously studied and that published maternal or infant drug-level data are unavailable. Pregnancy is not an appropriate setting for unsupervised supplementation because robust human pregnancy-safety data are lacking. Use during pregnancy or breastfeeding should be individualized by a qualified healthcare professional.

Hormone-Sensitive Conditions and Medicines

People with breast, uterine or ovarian cancer, unexplained vaginal bleeding, endometriosis or fibroids, and those using endocrine therapy, fertility medicines, hormonal contraception or menopausal hormone therapy should obtain specialist advice before use. This is a precaution based on incomplete interaction data and the herb’s investigation in hormone-related contexts, not proof that Shatavari is safe or harmful in every such condition.

Product Quality and Adverse Reactions

Supplement composition may differ from the label, and findings from one standardized extract may not apply to another product. Prefer products with clear botanical identity, root quantity or extract ratio, batch testing and contaminant controls. Stop use and seek care for rash, swelling, breathing difficulty, severe gastrointestinal symptoms or any other concerning reaction.

Who May Consider Shatavari—and Who Needs Clinical Guidance

Shatavari is most reasonably considered when its Ayurvedic indication and the available product-specific evidence fit the individual case. It should not be used as a generic “female tonic” without attention to diagnosis, life stage, medicines and product quality.

Conclusion

Shatavari has a well-defined Ayurvedic pharmacopoeial identity and a credible traditional role in nourishment, lactation and selected reproductive and digestive contexts. Human trials now provide encouraging short-term findings for lactation and menopausal or perimenopausal symptoms, but the results remain product-specific and do not justify a universal hormone-balancing claim. Antioxidant, antiulcer and stress-related findings remain primarily preclinical or limited to selected trial populations.

Disclaimer: This article is for educational purposes and does not replace diagnosis or treatment. Consult a qualified Ayurvedic practitioner and healthcare provider before using Shatavari, especially during pregnancy or breastfeeding, with hormone-sensitive conditions, chronic illness, unexplained symptoms or prescription medicines.

References

1. Ayurvedic Pharmacopoeia of India
2. Charaka Samhita — Shadvirechanashatashritiya Adhyaya
3. Steroidal saponins from the roots of Asparagus racemosus (2008), PubMed
4. Furostanol saponin and diphenylpentendiol from the roots of Asparagus racemosus (2012), PubMed
5. Chemical analysis reveals the botanical origin of shatavari products and confirms the absence of alkaloid asparagamine A in Asparagus racemosus (2013), PubMed
6. Randomized controlled trial of Asparagus racemosus (Shatavari) as a lactogogue in lactational inadequacy (1996), PubMed
7. NCBI
8. A Double-Blind Randomized Clinical Trial for Evaluation of Galactogogue Activity of Asparagus racemosus Willd (2011), PubMed Central
9. Postpartum Use of Shavari Bar® Improves Breast Milk Output: A Double-Blind, Prospective, Randomized, Controlled Clinical Study (2022), PubMed Central
10. Figshare (figshare.com)
11. Efficacy and Safety of Shatavari Root Extract for the Management of Menopausal Symptoms: A Double-Blind, Multicenter, Randomized Controlled Trial (2024), PubMed
12. Figshare (figshare.com)
13. Frontiersin (frontiersin.org)
14. Frontiersin (frontiersin.org)
15. Charaka Samhita — Rasayana Adhyaya
16. Asparagus racemosus modulates the hypothalamic-pituitary-adrenal axis and brain monoaminergic systems in rats (2013), PubMed
17. Asparagus racemosus attenuates anxiety-like behavior in experimental animal models (2014), PubMed
18. Identification of antioxidant compound from Asparagus racemosus (2004), PubMed
19. Antiulcer and antioxidant activity of Asparagus racemosus Willd and Withania somnifera Dunal in rats (2005), PubMed